Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Treasury Shares (2016 - 2025)

Dexcom (DXCM) has disclosed Treasury Shares for 8 consecutive years, with $2.1 billion as the latest value for Q4 2025.

  • On a quarterly basis, Treasury Shares rose 31.85% to $2.1 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $2.1 billion, a 31.85% increase, with the full-year FY2025 number at $2.1 billion, up 31.85% from a year prior.
  • Treasury Shares was $25.9 million for Q4 2025 at Dexcom, up from $20.6 million in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $25.9 million in Q4 2025 to a low of $100000.0 in Q1 2022.
  • A 5-year average of $9.3 million and a median of $7.4 million in 2022 define the central range for Treasury Shares.
  • Peak YoY movement for Treasury Shares: plummeted 62.7% in 2022, then soared 2002.14% in 2023.
  • Dexcom's Treasury Shares stood at $206.2 million in 2021, then skyrocketed by 188.55% to $595.0 million in 2022, then skyrocketed by 311.95% to $2.5 billion in 2023, then tumbled by 35.49% to $1.6 billion in 2024, then skyrocketed by 31.85% to $2.1 billion in 2025.
  • Per Business Quant, the three most recent readings for DXCM's Treasury Shares are $2.1 billion (Q4 2025), $1.8 billion (Q3 2025), and $1.6 billion (Q2 2025).